Purine synthesis pathway and nucleic acid incorporation

The purine synthesis pathway and nucleic acid incorporation encompass the biochemical processes required to generate adenine and guanine nucleotides, the fundamental components of DNA and RNA (Source: NCBI [1]). This target involves two main routes: the de novo synthesis pathway, which builds purines from basic molecules like amino acids and ribose-5-phosphate, and the salvage pathway, which recovers purines from degraded nucleic acids (Source: StatPearls [2]). In clinical practice, this pathway is targeted by antimetabolite drugs that mimic natural purines to inhibit rate-limiting enzymes such as inosine monophosphate dehydrogenase (IMPDH) or phosphoribosylpyrophosphate amidotransferase (PPAT) (Source: PubMed [3]). Furthermore, these drug analogs can be phosphorylated and incorporated into DNA or RNA strands, acting as fraudulent nucleotides that cause strand breaks, inhibit polymerases, and induce apoptosis (Source: Wikipedia [4]). Because rapidly proliferating cells, such as cancer cells and activated lymphocytes, are highly dependent on these pathways for genomic replication, they are particularly sensitive to such interventions. Consequently, targeting purine metabolism is a cornerstone in the treatment of leukemias, inflammatory bowel disease, and the prevention of organ transplant rejection (Source: NIH [5]).

Other names

Purine metabolismDe novo purine biosynthesisPurine salvage pathwayNucleotide synthesis

Inhibition of rate-limiting enzymes in purine biosynthesis (e.g., IMPDH, PPAT) and the incorporation of fraudulent purine analogs into DNA and RNA, leading to chain termination or mutagenesis and subsequent apoptosis.